KA2507

• Description:

  KA2507 is a potent, orally active and selective HDAC6 inhibitor, with an IC50 of 2.5 nM. KA2507 shows antitumor activities and immune modulatory effects in preclinical models[1].

• UNSPSC:

  12352005

• Target:

  HDAC

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage; Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/ka2507.html

• Concentration:

  10mM

• Purity:

  99.24

• Solubility:

  DMSO : 66.67 mg/mL (ultrasonic)

• Smiles:

  O=C (NO) C1=CC=C (CN (C2=NC=CN=C2) C3=NC=CN=C3) C=C1

• Molecular Formula:

  C16H14N6O2

• Molecular Weight:

  322.32

• References & Citations:

  [1]Apostolia M Tsimberidou, et al. Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors. Clin Cancer Res. 2021 May 4.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 2

• Isoform:

  HDAC6; HDAC8

• CAS Number:

  1636894-46-6